BIOGEN INC. Repayments of Short-term Debt
BIOGEN INC. (BIIB) reported Repayments of Short-term Debt of $2.43 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-05.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfShortTermDebt · last filed 2013-02-05
- BIOGEN INC. repayments of short-term debt for the quarter ending 2011-12-31 was -$1.00K, a 100.05% decline year-over-year.
- BIOGEN INC. repayments of short-term debt for the quarter ending 2011-09-30 was $4.21M, a 106.47% increase year-over-year.
- BIOGEN INC. repayments of short-term debt for the quarter ending 2011-06-30 was $5.13M, a 57.67% decline year-over-year.
- BIOGEN INC. repayments of short-term debt for the quarter ending 2011-03-31 was $2.11M, a 5.07% increase year-over-year.
- BIOGEN INC. repayments of short-term debt for fiscal 2012 was $2.43M, a 78.81% decline from fiscal 2011.
- BIOGEN INC. repayments of short-term debt for fiscal 2011 was $11.46M, a 36.60% decline from fiscal 2010.
- BIOGEN INC. repayments of short-term debt for fiscal 2010 was $18.07M, a 66.31% increase from fiscal 2009.
- BIOGEN INC. repayments of short-term debt for fiscal 2009 was $10.87M, a 99.28% decline from fiscal 2008.
| Period end | Repayments of Short-term Debt 3 month | Repayments of Short-term Debt 6 month | Repayments of Short-term Debt 6 month as first filed | Repayments of Short-term Debt 9 month | Repayments of Short-term Debt 12 month |
|---|---|---|---|---|---|
| 2012-12-31 | $2.43M 10-K · filed 2013-02-05 | ||||
| 2011-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $4.21M derived: sum of 2 quarters · filed 2013-02-05 | $9.35M derived: sum of 3 quarters · filed 2013-02-05 | $11.46M 10-K · filed 2013-02-05 | |
| 2011-09-30 | $4.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $9.35M derived: sum of 2 quarters · filed 2011-10-28 | $11.46M 10-Q · filed 2011-10-28 | $13.35M derived: sum of 4 quarters · filed 2013-02-05 | |
| 2011-06-30 | $5.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | $7.25M 10-Q · filed 2011-07-26 | $9.14M derived: sum of 3 quarters · filed 2013-02-05 | $11.18M derived: sum of 4 quarters · filed 2013-02-05 | |
| 2011-03-31 | $2.11M 10-Q · filed 2011-04-21 | $4.00M derived: sum of 2 quarters · filed 2013-02-05 | $6.04M derived: sum of 3 quarters · filed 2013-02-05 | $18.18M derived: sum of 4 quarters · filed 2013-02-05 | |
| 2010-12-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $3.93M derived: sum of 2 quarters · filed 2013-02-05 | $16.06M derived: sum of 3 quarters · filed 2013-02-05 | $18.07M 10-K · filed 2013-02-05 | |
| 2010-09-30 | $2.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $14.17M derived: sum of 2 quarters · filed 2011-10-28 | $16.18M 10-Q · filed 2011-10-28 | $16.18M derived: sum of 4 quarters · filed 2012-02-03 | |
| 2010-06-30 | $12.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | $14.14M 10-Q · filed 2011-07-26 | $14.14M derived: sum of 3 quarters · filed 2012-02-03 | $14.14M derived: sum of 4 quarters · filed 2012-02-03 | |
| 2010-03-31 | $2.01M 10-Q · filed 2011-04-21 | $2.01M derived: sum of 2 quarters · filed 2012-02-03 | $2.01M derived: sum of 3 quarters · filed 2012-02-03 | ||
| 2009-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $0.00 derived: sum of 2 quarters · filed 2012-02-03 | $10.87M 10-K · filed 2012-02-03 | ||
| 2009-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | $10.87M 10-Q · filed 2010-10-26 | |||
| 2009-06-30 | $10.87M 10-Q · filed 2010-07-20 | -$10.87M 10-Q · filed 2009-07-17 | |||
| 2008-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04 | $3.02B derived: sum of 2 quarters · filed 2011-02-04 | $1.51B 10-K · filed 2011-02-04 | ||
| 2008-09-30 | $3.02B derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-21 | $1.51B 10-Q · filed 2009-10-21 | |||
| 2008-06-30 | -$1.51B 10-Q · filed 2009-07-17 | ||||
| 2007-12-31 | $12.04M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |